Mind the gap: Ethical issues of private treatment in the public health system

New Zealand Medical Journal

Volumn 124, Issue 1334, 2011, Pages 89-96

  Fenton, Elizabeth ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; ETHICS; FUNDING; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE SYSTEM; HUMAN; NEW ZEALAND; PUBLIC HEALTH SERVICE;

HEALTH CARE COSTS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; NEOPLASMS; NEW ZEALAND; PRIVATE SECTOR; PUBLIC SECTOR;

EID: 79957859046     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Bloor, K. Should patients be able to pay top-up fees to receive the treatment they want? No. BMJ. 2008; 336:1105.
2. Brock, D. Ethical and Value Issues in Insurance Coverage for Cancer Treatment. Oncologist. 2010;15(suppl 1):36-42.
3. Brock, D. Ethical Issues in the Use of Cost Effectiveness Analysis for the Prioritization of Health Care Resources. In Anand, S, Peter, F, and Sen, A (eds.), Public Health, Ethics and Equity. Oxford: Oxford University Press, 2004.
4. Cancer Care Ontario. Report of the Provincial Working Group on the Delivery of Oncology Medications for Private Patients in Ontario Hospitals. 2006. Accessed at: www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13638
5. Chafe, R, Irfan, AD, Dobrow M, Sullivan T. Accessing unfunded cancer drugs in publicly funded hospitals. Lancet. 2009;10:306-7.
6. Cumming, J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ. 2010; 340:c2441.
7. Fojo T, Grady C. How Much is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. J Natl Cancer Inst. 2009;101:1044-48.
8. Hill S, Sarfati D, Blakely T, et al. Survival disparities in Indigenous and non-Indigenous New Zealanders with colon cancer: the role of patient comorbidity, treatment and health service factors. J Epidemiol Community Health. 2010;64:117-23.
9. Hurley J. Ethics, economics, and public financing of health care. J Med Ethics. 2001; 27:234-239.
10. Krohmal B, Emanuel, E. Access and Ability to Pay: The Ethics of a Tiered Health Care System. Arch Intern Med. 2007; 167:433-437.
11. PHARMAC. Response to 'Bridging the Gap' consultation. 8 February 2010.
12. Ramsey, S. How Should We Pay the Piper When He's Calling the Tune? On the Long-Term Affordability of Cancer Care in the United States. J Clin Oncol. 2007;25:175-179.
13. Richards, M. Improving access to medicines for NHS patients: A report for the Secretary of State for Health. 2008. Accessed at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_089927
14. Ryall T. Statement on 'Bridging the Gap.' 27 August 2010. Accessed at http://www.beehive.govt.nz/release/statement-039bridging-gap039
15. Schrag, D. The Price Tag on Progress - Chemotherapy for Colorectal Cancer. N Engl J Med. 2004;351:317-319.
16. Segall, S. Bringing the Middle Classes Back In: An Egalitarian Case for (Truly) Universal Public Services. Ethics and Economics. 2004; 2:1-7.
17. Southern Alliance - Otago and Southland District Health Boards. Bridging the Gap: A partnership between patients, doctors and DHBs to enhance access to unfunded treatments. Background material, 2010.